Novo strategy reset points to modest growth beyond obesity drugs

Traders Union
All News
Financial News
Novo strategy reset for growth

Highlights

Novo presented a new strategy aiming for at least five multi-blockbuster drugs by 2030 and to expand oral Wegovy capacity tenfold to reach 15 million patients.
Novo shares dropped 8 per cent on Monday as investors reacted to restrained growth targets and intensifying pricing pressure in the obesity drugs market, fueled by Eli Lilly competition.
Novo targets 50 per cent growth in blood and endocrine disorders by 2030 and overall annual growth of about 5 per cent through 2030, roughly matching industry peers.

Strategy targets broader drug pipeline

As reported by Financial Times, Novo set out a plan centered on expanding capacity for weight-loss pills, developing a new generation of obesity and diabetes treatments, and widening its presence in blood and endocrine disorders and liver diseases.

The Danish drugmaker says it wants to have at least five multi-blockbuster medicines by 2030. Management also plans to build oral Wegovy capacity to serve roughly 10 times more patients than the current 1.5 million, taking potential reach to about 15 million people.

Even so, that target appears restrained against the scale of the obesity market. Novo estimates that as many as 2 billion people worldwide are living with obesity, suggesting that broader access to effective pills could expand demand far beyond the capacity now being outlined.

Investor pressure and market economics

Novo shares fell about 8 per cent on Monday as the strategy was presented, indicating that investors remain unconvinced the group can regain the momentum it once had when it ranked as Europe’s most valuable listed company.

Pricing pressure in obesity drugs is also intensifying. Competition with Eli Lilly is pushing the market toward lower prices, while more pharmaceutical groups are trying to enter with their own pills and next-generation treatments, making it harder for Novo to rebuild the earnings profile that supported its earlier peak valuation.

The move into diseases linked to obesity may offer a broader base for growth, but the company’s targets there also look cautious. Its aim for 50 per cent growth in blood and endocrine disorders by 2030 is roughly in line with the division’s current pace, according to analysts at ABG Sundal Collier, and overall Novo expects growth only in line with peers, implying about 5 per cent a year through 2030.

Our earlier report on Eli Lilly’s manufacturing expansion for obesity medicines outlined how the company is ramping up production capacity for its GLP-1 pill Foundayo as demand rises in the U.S. We noted Lilly’s plan to bring a new Houston facility online by 2030 as part of a wider multibillion-dollar buildout aimed at strengthening supply and narrowing the competitive gap with Novo in weight-loss treatments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.